3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
302
Parkinson Disease 4, Autosomal Dominant Lewy Body
180
Melanoma
166
Neoplasms
133
Squamous Cell Carcinoma of Head and Neck
126
Neoplasm Metastasis
98
Colorectal Neoplasms
96
Carcinoma, Renal Cell
80
Triple Negative Breast Neoplasms
75
Head and Neck Neoplasms
72
Stomach Neoplasms
70
Lung Neoplasms
68
Breast Neoplasms
60
Ovarian Neoplasms
56
Carcinoma, Transitional Cell
51
Uterine Cervical Neoplasms
44
Endometrial Neoplasms
44
Pancreatic Neoplasms
43
Urinary Bladder Neoplasms
40
Esophageal Neoplasms
40
Carcinoma, Hepatocellular
37
Small Cell Lung Carcinoma
30
Cholangiocarcinoma
24
Prostatic Neoplasms
22
Carcinoma
22
Lymphoma
20
Carcinoma, Squamous Cell
20
Recurrence
17
Sarcoma
16
Esophageal Squamous Cell Carcinoma
16
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Sunitinib
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Gemcitabine
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urologic Diseases
×
pembrolizumab
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT03123055
2020-03-18
FIERCE-22
Rainier Therapeutics
Phase 1/2
Terminated
28 enrolled
8 charts